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Introduction	
Critical	care	is	a	high	risk	medication	area	where	vulnerable,	acutely	unwell	patients	are	
treated	with	intense	therapies	in	a	complex	environment.		As	well	as	critical	illness,	patients	
are	often	older	and	with	multiple	co-morbidities	[1].		The	presence	of	multiple	organ	failure	
adds	to	the	complexity	of	medication	regimes	in	the	individual	patient.		There	is	both	a	high	
rate	of	parenterally	administered	medication	and	a	high	risk	of	prescribing	error.		The	
frequent	lack	of	mental	capacity	of	patients,	prevents	them	contributing	to	medication	
reviews	or	taking	responsibility	for	medicines	administration,	and	increases	their	
vulnerability	to	erroneous	or	suboptimal	medication	therapy.		
	
There	is	much	evidence	to	support	the	need	for	clinical	pharmacists	(CPs)	in	the	care	of	
critically	ill	patients.		CPs	have	been	demonstrated	as	essential	to	improving	medicines	
safety	both	at	an	individual	and	a	broader	critical	care	organisational	level	[2-5].			There	is	
also	a	wealth	of	evidence	existing	to	demonstrate	the	value	of	CPs	in	critical	care,	showing	a	
significant	positive	impact	on	patient	care,	particularly	in	relation	to	improved	safety,	
medicines	optimisation,	reduced	expenditure	and	reduced	length	of	stay	[6-9].		
	
Pharmacist	interventions	include	identification	of	‘errors’	(rectification	of	incorrect	
prescribing,	including	omissions),	‘optimisation’	(the	enhancement	of	a	patient’s	medication	
to	improve	efficacy	of	therapy)	or	a	‘consult’	(reactive	provision	of	advice	to	a	healthcare	
professional	regarding	a	specific	issue)	[10].		Whilst,	anecdotally,	many	hospitals	collect	
intervention	data	from	their	pharmacy	teams,	this	is	rarely	analysed	in	depth	and,	to	our	
knowledge,	there	has	been	no	larger	scale	multi-site	study	collecting	and	reviewing	CP	
interventions	in	critical	care.		The	Expert	Practice	Development	Group	(EPDG)	of	the	United	
Kingdom	Clinical	Pharmacy	Association	(UKCPA)	is	composed	of	pharmacists	with	expertise	
in	critical	care	(including	consultant	pharmacists,	regional	representation	and	extensive	
experience	in	critical	care	pharmacy).		In	2011,	the	EPDG	undertook	to	collaborate	on	the	
first	multi-site	study	relating	to	CP	activity.		In	2012,	this	study	became	known	as	
PROTECTED-UK	(Pharmacist’s	Review	and	Outcomes:	Treatment	Enhancing	Contributions	
Tallied,	Evaluated	and	Documented),	with	the	first	paper	published	in	2015	[11].	The	results	
of	PROTECTED-UK		demonstrated	that	CP	interventions	were	made	in	nearly	one	in	six	of	all	
prescriptions	reviewed,	and	that	two	thirds	of	these	interventions	were	of	moderate	or	high	
clinical	impact.		A	prescription	is	defined	as	a	single	item	prescribed;	therefore,	review	of	a	
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patient	may	include	multiple	prescriptions.		Of	these	interventions,	2,953	(87.1%)	were	
proactive,	where	the	intervention	was	identified	by	the	CP	without	prior	involvement	of	a	
healthcare	professional.	The	breakdown	of	intervention	type	was	6.8%	error,	8.3%	
optimisation	and	1%	consultation,	of	all	prescriptions	reviewed.		The	great	majority	of	
interventions	-	2,967	(87.5%)	-	were	accepted	by	the	inter-professional	team.			
What	was	not	shared	in	the	earlier	manuscript	was	the	nature	of	the	CP	intervention	and	
characteristics	of	the	clinical	pharmacy	service	and	how	these	contribute	to	patient	care.		
	
	The	recent	Faculty	of	Intensive	Medicine	(FICM)	and	Intensive	Care	Society	(ICS)	standards	
on	staffing,	specifies	daily	input	of	the	pharmacist	on	the	interprofessional	ward	round,	
ideally	provided	seven	days	a	week	[12].		Despite	these	standards,	earlier	national	surveys	
have	demonstrated	that	provision	of	pharmacy	services	varies	amongst	hospitals	in	the	UK,	
both	in	terms	of	pharmacist-to-patient	bed	ratio,	and	level	of	expertise	of	the	CP	providing	
the	service	[13].		The	FICM/ICS	standards	state	that	sole	pharmacist	practitioners	on	critical	
care	should	be	of	an	Advanced	Stage	II	standard,	with	a	broad	range	of	clinical	expertise.		If	
the	practitioners	work	as	a	team,	there	should	be	a	range	of	CPs	(from	Foundation	to	
Mastery),	including	the	support	of	clinical	pharmacy	technicians.		These	levels	of	expertise	
correlate	to	the	recently	introduced	(UK)	Royal	Pharmaceutical	Society’s	Faculty	
accreditation	system	for	post-Foundation	training	[14]	which		provides	a	quality	assured	
credentialing	system.		Pharmacists	are	now	able	to	provide	evidence	to	support	a	credential	
at	advance	practice	Stage	I	(established,	experienced	practitioners),	Stage	II	(expert	
practitioners)	or	Stage	III	(Fellowship,	consultant	or	exceptional	practice).		Prior	to	this	
national	initiative	(and	during	the	study	period)	-	which	continues	to	be	rolled	out	to	the	
workforce	–	defining	level	of	practice	remains	a	challenge.		Consequently,	pharmacist	grade,	
according	to	National	Health	Service	(NHS)	Agenda	for	Change	banding,	is	often	used	as	a	
surrogate	indicator	of	level	of	practice,	despite	clear	limitations	(Table	3).		Whilst	the	
expectation	might	be	that	the	greater	the	expertise	of	the	pharmacist,	the	higher	the	impact	
of	the	intervention,	there	is	a	lack	of	corroborating	evidence	to	date.	
	
The	aim	of	this	paper	was	to	determine	factors	affecting	the	interventions	made,	specifically	
examining	the	relationships	between:	
• Intervention	and	grade	of	pharmacy	staff	
• Number	of	prescriptions	reviewed	and	demographics	of	the	service	provided	within	the	
hospital,	including	number	of	patient	beds,	ward	round	attendance,	pharmacist	
prescribers	
• Day	the	interventions	were	made.		
	
Method	
PROTECTED-UK	was	a	prospective	descriptive	study	of	self-reported	clinical	interventions	
undertaken	by	pharmacy	staff,	conducted	in	21	adult	critical	care	units	across	the	UK	over	a	
14	day	period	from	5-18th	November	2012,	capturing	all	interventions	reported	by	the	
critical	care	pharmacy	team.		The	trial	period	of	14	days	was	chosen	as	a	balance	of	
pragmatism,	with	the	inclusion	of	at	least	two	weekends	and	within	a	calendar	period,	
where	annual	leave	or	calendar	events	were	least	likely	to	influence	the	data	capture.	
An	online	survey	was	developed	to	record	pharmacist	and	pharmacy	service	demographics	
of	the	study	site.		All	members	of	the	EPDG	were	encouraged	to	participate	in	this	study.		A	
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detailed	description	of	the	methodology	and	site	demographics	can	be	found	in	the	first	
paper	[11].	
	
Interventions	
Interventions	were	defined	as	contributions	to	care	aimed	at	improving	patient	care,	and	
classed	as	‘error’	(A	medication	error	was	defined	as	an	error	in	the	process	of	prescribing,	
dispensing,	preparing,	administering,	monitoring,	or	providing	medicine	
advice,	regardless	of	whether	harm	has	occurred	[2,	15],	‘optimisation’	(defined	as	a	
proactive	contribution	that	sought	to	enhance	patient	care)	or	a	‘consult’	(reactive	
intervention	in	response	to	a	request	from	a	member	of	the	MDT	for	an	CP	review	).		At	
each	site,	each	critical	care	pharmacy	team	member	recorded	their	interventions,	which	
they	provided	as	part	of	their	routine	clinical	service.		All	intervention	data	were	recorded	
on	a	bespoke	password-protected	web	portal	database	in	real	time,	with	all	identifiable	
patient	specific	data	anonymised.		The	details	recorded	included	a	short	description	of	the	
intervention,	medication	involved,	type	of	intervention,	grade	of	clinical	impact	as	decided	
by	reporting	pharmacist,	acceptance	rate	and	patient	outcome	(positive	or	negative).		Each	
intervention	included	the	grade	of	pharmacy	staff	involved.		This	data	was	exported	into	
SPSS	version	22	(IBM)	from	an	SQL	file.	SPSS	data	file	was	examined	for	variable	
correspondence	with	the	SQL	file.		Coding	of	the	data,	investigating	missing	data	and	
clarification	of	ambiguous	data	was	undertaken.	
	
The	activity	data	of	the	clinical	pharmacy	team	were	also	recorded	in	the	web-portal,			daily,	
in	terms	of	time	involved	in	clinical	activity,	and	numbers	of	patients	and	prescriptions	
reviewed.		Practitioners	were	provided	with	definitions	and	supporting	‘help	files’	on	the	
web-portal.		To	address	data	consistency,	data	entry	fields	were	format	locked	to	reduce	
typographical	entries	or	field	input	errors.		The	web-portal	itself,	the	field	entry	formats	and	
the	on-screen	form	layout	were	piloted	before	start	of	the	study	period.	
To	assess	relevant	denominators,	the	following	data	sets	were	recorded:	the	number	of	
medication	orders	(new	prescriptions)	reviewed	each	day	(on	day	one,	all	medication	orders	
were	regarded	as	new)	and	the	number	of	patients	reviewed.		The	type	of	intervention	was	
characterised	according	to	a	previously	used	classification	[16].		The	proportion	of	
interventions	accepted	by	the	team	(or	self-prescribed	by	independent	prescriber	
pharmacists)	was	also	recorded.	
	
Clinical	impact	coding		
Each	intervention	was	graded	for	potential	clinical	impact	to	patient	care.	The	ordinal	scale	
utilised	is	well	established	to	grade	medication	errors	[2].		The	optimisation	and	consult	
scale	were	specifically	developed	for	PROTECTED-UK,	to	mirror	the	errors	scale	i.e.low,	
moderate,	high	and	life-saving	impact.	
	
All	collated	interventions	were	blind-graded	by	one	of	the	principal	investigators,	a	CP,	for	
the	purposes	of	consistency.		Where	the	grading	was	the	same	as	the	recording	pharmacist,	
this	was	considered	the	final	grade.		If	there	was	a	difference,	the	intervention	was	blind-
graded	by	one	of	two	consultant	pharmacist	investigators.		Where	these	two	grades	agreed,	
this	was	considered	the	final	grade.		If	all	three	grades	disagreed,	then	a	critical	care	
consultant	physician	blind-graded	the	intervention	and	the	final	grade	was	where	two	
grades	agreed.			
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Pharmacy	and	Critical	Care	Service	Survey	
An	online	survey	was	designed	using	www.surveymonkey.co.uk	in	order	to	record	the	
demographics	of	each	of	the	participating	units	and	clinical	pharmacy	teams.		The	number,	
grade	of	clinical	pharmacist,	and	whether	a	consultant	pharmacist	led	the	team	were	
recorded.		Further	data	included:	type	of	unit	(general	or	specialist);	utilisation	of	electronic	
prescribing;	‘developed’	(defined	as	more	than	one	practitioner	in	the	team)	or	
‘undeveloped’	pharmacy	service;	the	presence,	scope	and	grade	of	independent		prescriber;		
presence	of	a	weekend	clinical	pharmacy	service,	and	finally	the	method	of	communication	
back	to	the	interprofessional	team	(team	meeting,	self-prescribed	interventions,	individual	
feedback	to	junior	doctors,	bedside	ward	round	or	‘other’).			
	
Analysis	
Bivariate	analysis	was	conducted	using	SPSS	version	22	(IBM).		The	data	were	analysed	for	
central	tendency.		Multiple	regression	was	not	feasible	as	many	of	the	factors	were	not	
independent	factors.		A	p	value	<0.05	was	considered	statistically	significant,	and	the	
correlation	coefficients	(r	values)	were	reported	as	an	indication	of	the	strength	and	
direction	of	the	relationship	between	the	factors	analysed.		Chi	test	was	used	for	explore	
the	relationship	between	pharmacy	staff	grading	and	intervention	rate.	
	
The	intervention	rate	was	defined	as	the	number	of	interventions	divided	by	the	number	of	
prescriptions	reviewed.		The	same	calculation	was	applied	to	error	rate,	optimisation	rate	
and	consult	rate.		The	rate	of	each	intervention	type	was	then	checked	for	correlation	
against	the	pharmacy	and	critical	care	service	factors.		
	
Ethical	Considerations	
The	study	was	deemed	a	clinical	audit	after	with	discussion	with	Research	and	Development	
(R&D)	at	University	College	London	(UCL),	the	lead	site,	and	the	need	for	ethics	approval	
was	waived.		It	was	consequently	registered	as	a	clinical	audit	at	each	participating	site,	in	
line	with	local	requirements.	
	
Results		
The	majority	of	results	were	analysed	solely	on	the	weekday	data.		The	weekend	
intervention	numbers	were	relatively	low	and	reported	separately.		A	breakdown	of	
individual	unit	activity	is	provided	(table	1).	
	
Table	1.	
	
Time	Spent	on	Prescription	Review	
The	mean	time	spent	on	the	ward	per	pharmacist	was	3.5	hours	per	day	(±SD	1.7).	Each	
pharmacist	reviewed	a	mean	of	10.3	patients	per	day	(±SD	4.2),	and	spent	22.5	(±SD	9.5)	
minutes	per	patient	review.		A	mean	of	1.2	(±SD	0.6)	interventions	were	made	per	patient	
seen.	The	intervention	rate	had	a	moderate	inverse	correlation	with	both	the	number	of	
prescriptions	reviewed	and	the	total	number	of	patients	reviewed	daily	(p	=	0.02,	r=-0.5	and	
p=0.02,	r=-0.5	respectively.		The	length	of	time	the	pharmacist	spent	on	the	ward	also	had	a	
moderate	inverse	correlation	with	the	intervention	rate	(p	=	0.05,	r=-0.4).		There	was	a	
strong	inverse	correlation	between	the	optimisation	rate	and	daily	prescriptions	reviewed	(p	
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=	0.001,	r=-0.7)	and	a	moderate	inverse	association	with	the	total	number	of	patients	
reviewed	daily	(p	=	0.02,	r=-0.5).	
	
Weekday	and	Weekend	Service	Provision	
When	weekdays	were	broken	down	into	individual	days,	Monday	had	the	highest	
intervention	rate	(24.1%)	and	Friday	the	lowest	(17.0%).		The	greatest	number	of	patients	
were	reviewed	on	a	Monday,	as	well	as	a	statistically	significantly	greater	number	of	new	
drug	orders	reviewed	(p	=	0.038).		The	total	pharmacy	time	spent	reviewing	patients	on	the	
ward	was	similar	across	all	weekdays	with	a	mean	of	5.7	hours	(±SD	=	0.19).	
	
Of	the	21	units	with	a	proactive	clinical	pharmacy	service,	only	two	provided	a	specialist	
service	at	weekends	(Saturdays	only,	at	the	time	of	the	study),	with	the	other	units	
predominantly	providing	an	on-call,	reactive	service	for	emergencies,	or	a	dispensary-based	
service.			A	greater	intervention	rate	was	seen	on	weekends	compared	with	weekdays	
(Table	2);	33.6%	and	16.1%	respectively	(p	<0.0001).		Of	the	weekend	interventions,	the	
majority	(89%)	were	optimisations,	with	83.9%	of	moderate,	or	high	clinical	impact.		Five	of	
the	units	without	a	specialist	weekend	service	also	recorded	interventions;	15	in	total.		
These	were	from	dispensary	or	on-call	shifts.		At	weekends,	there	is	a	lower	than	expected	
frequency	of	errors	(4.2%	at	weekends	against	42.3%	on	weekdays,	χ2	=	56.59	p<0.0001)	
and	a	peak	in	error	reporting	on	Mondays.		This	could	imply	that	errors	are	being	missed	or	
less	frequently	identified	at	weekends,	and	may	represent	a	period	of	increased	patient	risk.	
 
The	initial	data	entry	for	‘impact’	was	made	by	the	practitioner.	Subsequently,	an	
independent	clinician	provided	a	blinded	impact	assessment	of	the	case	entry.	Cases	with	
disagreement	between	the	impact	scores	were	subsequently	blindly	reviewed	by	a	third	
independent	clinician.		Any	cases	where	there	was	disagreement	between	all	three	scores	
prompted	a	fourth	blinded	assessment	and	a	majority	decision.	In	all,	there	was	
disagreement	in	1655	(49.0%)	of	cases	after	the	first	independent	impact	scoring,	which	
resolved	to	110	(3.3%)	of	cases	of	disagreement	following	a	second	round	assessment	
before	consensus.	
	
Table	2.	
	
Grade	of	Pharmacist	
The	relationship	between	the	grade	of	pharmacist	and	interventions	made	was	also	
investigated,	however	the	correlation	between	impact	of	intervention	and	grade	of	
pharmacist	was	not.		The	presence	of	a	consultant	pharmacist	had	a	moderate	inverse	
correlation	with	the	error	rate	detection	of	the	unit	(p=0.008,	r=-0.6).		An	explanation	of	UK	
pharmacist	gradings	can	be	found	in	Table	3.		Consultant	pharmacists	made	the	most	
interventions	per	prescription	reviewed	(22.6%),	followed	by	pharmacy	technicians	(17.6%)	
whose	interventions	were	in	relation	to	medicines	reconciliation	(Table	3).		Consultant	
pharmacists	were	also	more	likely	to	intervene	in	the	form	of	a	consult.		Junior	pharmacists	
made	the	lowest	number	of	interventions	per	prescription	reviewed	(11.1%).		Band	8a	
pharmacists	reviewed	the	most	prescriptions,	with	a	total	of	7825	items,	and	had	an	
intervention	rate	of	15.0%	(p	<0.0001,	χ2	=	37.7).			
	
Table	3.	
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Other	Factors	
There	was	no	correlation	between	the	presence	of	electronic	prescribing	on	the	critical	care	
unit	and	any	of	the	intervention	rates.		This	was	also	found	for	‘developed/undeveloped	
pharmacy	team’	and	specialised	versus	general	units.	However,	moderate	positive	
associations	were	found	for	the	presence	of	non-medical	prescribing	(excluding	pharmacist	
prescribers)	and	overall	intervention	rate	and	optimisation	rate	(p=0.04,	r=0.5	and	p=0.02,	
r=0.5	respectively).			
	
Discussion	
The	study	results	demonstrate	the	clinical	impact	clinical	pharmacists	routinely	have	on	
patient	care	in	critical	care	units.		As	described	in	the	earlier	paper,	there	was	a	mean	
intervention	rate	of	one	intervention	per	six	prescriptions	reviewed	[11].		None	of	the	sites	
that	participated	in	PROTECTED-UK	had	an	intervention	rate	of	zero.		This	could	imply	that	
hospitals	in	the	UK	that	do	not	provide	a	clinical	pharmacy	service	to	their	critical	care	units	
could	be	compromising	patient	care	by	not	facilitating	daily	CP	review.		
	
Intervention	rates	were	inversely	correlated	with	the	number	of	prescriptions	and	patients	
the	pharmacist	reviewed.		As	far	as	we	are	aware,	this	is	the	first	piece	of	work	to	
demonstrate	that	CP	review	takes	time,	and	that	to	achieve	full	effect	from	a	clinical	
pharmacy	service	providers	must	ensure	that	units	are	adequately	staffed.	
	
Error	rates	also	inversely	correlated	with	the	presence	of	a	consultant	pharmacist,	which	
could	suggest	the	presence	of	a	consultant	pharmacist	leads	to	more	effective	prescribing	
error	reduction,	although	given	the	low	numbers	of	these	posts	within	UK	critical	care,	
results	are	hard	to	extrapolate	conclusively.	A	recent	review	found	that	pharmacists	had	no	
significant	impact	on	general	medication	error	reduction,	however	they	were	more	likely	to	
reduce	preventable	errors	[17].	An	accompanying	editorial	suggests	that	CP	impact	on	
patient	care	is	related	to	experience	and	clinical	training,	supporting	the	results	found	in	our	
study	[18].	
	
In	terms	of	pharmacist	grade,	as	a	pharmacist’s	knowledge	and	skills	increase	it	is	expected	
that	their	role	in	critical	care	will	change	in	a	more	proactive	way,	with	more	consultations,	
optimisations	and	overall	higher	impact	intervention,	which	is	demonstrated	in	the	reported	
data.		A	lower	intervention	rate	was	observed	with	junior	pharmacists.	This	could	be	
attributed	to	their	limited	specialist	knowledge.			Contrary	to	this	was	the	observation	that	
pharmacy	technicians	had	the	second	highest	intervention	rate	after	consultant	
pharmacists,	88.2%	of	these	were	in	medicines	reconciliation.	This	clearly	demonstrates	
their	review	of	medication	on	admission	and	the	meticulous	attention	to	detail	they	take	in	
getting	the	medicines	reconciliation	right.	
	
These	data	also	supports	the	ICS	staffing	recommendations	that	sole	practitioners	should	be	
of	at	least	an	8a	level	and	pharmacists	working	in	teams	should	reflect	a	skill	mix,	preferably	
led	by	a	consultant	pharmacist	in	larger	centres	[19].			
	
The	data	suggest	that	for	a	nine-bedded	critical	care	unit,	a	CP	needs	at	least	three	hours	of	
clinical	time	to	effectively	review	all	patients,	producing	an	intervention	rate	of	1.16	
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interventions	per	patient	reviewed.	This	is	in	line	with	ICS	standards	which	recommend	0.1	
whole	time	equivalent	(WTE)	of	a	CP	for	level	3	patients,	and	0.05WTE	for	level	2	patients.		
Importantly,	the	data	do	not	distinguish	differences	between	the	length	of	time	needed	to	
review	a	level	3	patient,	and	level	2	patient.		One	would	anticipate	a	longer	review	time	
would	be	needed	for	sicker	patients,	due	to	their	complexity,	both	in	terms	of	medication	
and	co-morbidities.			
In	addition,	increased	time	is	needed	at	both	admission	and	discharge;	admission,	in	order	
to	fully	review	the	patient	and	undertake	medicines	reconciliation	and	discharge,	to	ensure	
that	medications	have	been	reviewed	and	appropriately	discontinued	or	reinitiated	[19].		
In	units	currently	understaffed	with	CPs,	consideration	should	be	given	to	increase	staffing	
to	national	ICS	standards,	which	would	be	expected	to	increase	time	available	for	
appropriate	patient	review	as	well	as	increase	the	intervention	rate	with	patient	safety	
benefits	[4,	5].		Importantly,	the	clinical	pharmacy	workforce	should	also	be	considered	and	
essential	supporting	clinical	technicians	included	wherever	feasible.	
		
CP	interventions	undertaken	to	correct	a	medication	error	accounted	for	only	around	40%	
of	all	interventions	recorded	in	this	study.		This	is	a	similar	proportion	to	those	found	in	
other	studies	[20,	21].		The	majority	of	interventions	were	optimisations	or	consults.	The	
importance	of	these	data	is	that	it	clearly	demonstrates	a	progression	in	CP	practice,	from	
one	historically	regarded	as	primarily	focused	on	detecting	errors	in	prescribing,	to	one	that	
includes	consideration	of	evidence	and	individual	patient	variability	in	terms	of	medicines	
optimisation.	
	
Several	studies	conducted	in	critically	ill	populations	have	largely	demonstrated	higher	
mortality	rates	associated	with	admission	during	weekends	and	out	of	hours	[22-28].	The	
intervention	rate	in	this	study	was	substantially	higher	at	weekends,	with	an	intervention	
made	every	three	prescriptions.		Of	these	interventions,	the	high	proportion	(83.9%)	of	
moderate	or	high	impact	graded	interventions	suggest	that	CP	input	at	weekends	is	
essential	to	reduce	harm	from	medication	errors,	and	optimise	pharmacotherapy.		This	data	
could	also	demonstrate	that	the	quality	of	patient	care	is	currently	diminished	at	the	
weekend	in	units	that	do	not	provide	a	clinical	pharmacy	service.	
	
Despite	an	intervention	rate	of	more	than	double	the	weekday	rate,	a	lower	percentage	of	
these	interventions	were	accepted	by	the	team.	This	could	be	attributed	to	a	number	of	
factors,	including	on-call	medical	staff	being	less	familiar	with	patients	and	less	confident	to	
make	changes	in	their	medication,	reduced	availability	of	prescribers	or	lastly,	that	the	CP	
did	not	always	have	time	to	complete	the	intervention	process.	Whatever	the	reason,	
developments	in	the	number	of	independent	pharmacist	prescribers	in	this	speciality	will	be	
expected	to	improve	pharmacy	and	medical	staff	efficiency	in	this	aspect	[29].		Extension	of	
critical	care	pharmacy	services	to	full	weekend	provision,	as	recommended	by	the	ICS,	
should	be	considered	so	that	all	critical	care	patients	have	access	to	clinical	pharmacy	
review.		This	is	now	a	future	directive	for	both	the	pharmacy	profession	and	the	UK	
deliverers	of	critical	care	[30].		
	
Limitations	
The	units	involved	in	the	study	were	heterogeneous,	with	a	wide	range	of	pharmacy	
expertise,	pharmacist-to-patient-bed	ratios,	patient	illness	severities	and	different	types	of	
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pharmacy	service	provided.		A	number	of	hospitals	were	treated	as	a	single	unit	whilst	
others,	with	multiple	sites,	reported	each	separately.		Interventions	were	reported	and	
graded	by	the	individual	pharmacists	on	the	units,	which	may	cause	variation	in	data	
collection	and	bias	due	to	self-reporting.		However,	the	moderation	process	should	have	
addressed	some	of	the	variation.		There	is	a	potential	for	under-reporting	and	recall	bias,	
although	the	majority	of	interventions	were	recorded	close	to	the	time	of	intervention	and	
should	have	minimised	this.		Units	self-defined	as	‘developed/undeveloped’	and	may	
represent	a	simplistic	assessment	of	the	resources	available	which	may	reduce	medication	
errors	in	practice.	
	
Conclusions	
These	results	demonstrate	that	every	patient	cared	for	in	the	ICU	should	have	daily	
prescription	review	by	a	clinical	pharmacist.		We	have	demonstrated	that	CPs	reduce	
medication	errors	and	optimise	pharmacotherapy,	with	a	high	intervention	rate	per	number	
of	prescriptions	reviewed.		However,	intervention	rate	is	proportional	to	time	spent	
reviewing	a	patient	and	thus	appropriate	pharmacy	workforce	(number	and	practitioner	
levels)	levels	are	essential.	On	weekdays,	optimisations	and	consults	accounted	for	the	
majority	of	all	interventions,	with	the	remaining	interventions	involving	medication	error	
correction,	demonstrating	a	shift	in	the	role	of	the	CP	over	the	last	two	decades.		Lastly,	the	
higher	intervention	rate	on	the	units	that	provided	a	weekend	service	highlights	the	need	
for	clinical	pharmacy	services	in	critical	care	seven	days	a	week.		In	summary,	this	study	
demonstrates	the	need	for	specialist	pharmacists,	in	sufficient	numbers,	to	be	integral	to	
the	provision	of	high	quality	critical	care	in	the	United	Kingdom	(UK).	
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Table	1:	Interventions	and	Charts	Reviewed	Per	Critical	Care	Unit	During	the	Weekday	
U
nit	
Total	Tim
e	(hrs)	Spent	
on	U
nit	D
uring	Study
a	
Total	num
ber	of	patients	
review
ed	(M
ean)	
Interventions	Per	D
ay	
(M
ean)	
Prescriptions	review
ed	
(Total)	
Errors	
O
ptim
isations	
Consult	
Interventions	M
ade	
(Total)	
Intervention	Rate	
Prescriptions	Review
ed	
Per	Intervention	
1	 81.0	 23.8	 30.5	 1415	 141	
10.0%	
121	
8.5%	
43	
3.0%	
305	
	
21.6%	 4.6	
2	 142.5	 33.3	 31.0	 2480	 162	
6.5%	
147	
5.9%	
1	
0.0%	
310	 12.5%	 8.0	
3	 194.5	 57.2	 32.9	 4206	 99	
2.4%	
197	
4.7%	
33	
0.8%	
329	 7.8%	 12.8	
4	 64.0	 17.1	 14.4	 911	 112	
12.3%	
29	
3.2%	
3	
0.3%	
144	 15.8%	 6.3	
5	 35.0	 7.5	 11.0	 356	 50	
14.0%	
53	
14.9%	
7	
2.0%	
110	 30.9%	 3.2	
6	 12.0	 4.1	 9.5	 250	 42	
16.8%	
52	
20.8%	
1	
0.4%	
95	 38.0%	 2.6	
7	 23.8	 6.1	 9.5	 337	 23	
6.8%	
56	
16.6%	
16	
4.7%	
95	 28.2%	 3.5	
8	 33.5	 15.5	 26.3	 845	 147	
17.4%	
112	
13.3%	
4	
0.5%	
263	 31.1%	 3.2	
9	 24.0	 13.6	 9.3	 779	 20	
2.6%	
44	
5.6%	
29	
3.7%	
93	 11.9%	 8.4	
10	 56.8	 14.4	 20.6	 1268	 95	
7.5%	
84	
6.6%	
27	
2.1%	
206	 16.2%	 6.2	
11	 22.0	 10.6	 8.9	 521	 15	
2.9%	
59	
11.3%	
15	
2.9%	
89	 17.1%	 5.9	
12	 40.5	 6.8	 11.3	 328	 46	
14.0%	
67	
20.4%	
0	
0.0%	
113	 34.5%	 2.9	
13	 48.0	 15.3	 8.6	 730	 8	
1.1%	
65	
8.9%	
13	
1.8%	
86	 11.8%	 8.5	
14	 19.5	 5.7	 4.2	 166	 25	
15.1%	
14	
8.4%	
3	
1.8%	
42	 25.3%	 4.0	
15	 58.8	 17.2	 15.9	 1309	 74	
5.7%	
78	
6.0%	
7	
0.5%	
159	 12.1%	 8.2	
16	 19.0	 10.4	 4.2	 853	 21	
2.5%	
20	
2.3%	
1	
0.1%	
42	 4.9%	 20.3	
17	 93.0	 14.6	 14.3	 605	 12	
2.0%	
131	
21.7%	
0	
0.0%	
143	 23.6%	 4.2	
18	 85.5	 14.0	 16.4	 1343	 9	
0.7%	
152	
11.3&	
3	
0.2%	
164	 12.2%	 8.2	
19	 37.5	 5.0	 7.5	 301	 2	
0.7%	
73	
24.3%	
0	
0.0%	
75	 24.9%	 4.0	
20	 43.0	 18.1	 6.8	 504	 6	
1.2%	
60	
11.9%	
2	
0.4%	
68	 13.5%	 7.4	
21	 36.5	 15.5	 36.3	 1010	
	
284	
28.1%	
79	
7.8%	
0	
0.0%	
363	 35.9%	 2.8	
	 55.7	
(mean)	
15.5	
(mean)	
15.7	
(mean)	
20517	
(total)	
1393	
6.8%	
1693	
8.3%	
208	
1.0%	
3294	
(total)	
16.1%	
(mean)	
6.2	
(mean)	
aTotal	time	all	pharmacy	team	members	spent	on	unit	over	study	period	
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Table	2:	Interventions	by	Weekdays	and	Weekends	
	 Weekdays	
(Average	Day)	
Weekends	
(Saturdays)	
Number	of	hospitals	with	proactive	clinical	
pharmacy	service	
21	 2	
Number	of	interventions	addressed	by	
pharmacy	team	
3294	 81	
Prescriptions	reviewed	by	pharmacy	team	 20517	 241	
Intervention	ratea	 16.1%	 33.6%	
Proactive	interventionsb	 2865	(87.0%)	 78	(96.0%)	
Interventions	accepted	by	interprofessional	
team	
2887	(87.6%)	 67	(82.7%)	
aNumber	of	prescriptions	intervened	on	by	pharmacy	team	divided	by	the	prescriptions	reviewed	
bProblem	identified	by	intervening	pharmacy	team	member	without	being	approached	by	another	healthcare	professional	
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Table	3:	Intervention	Rate	By	Grade	of	Pharmacy	Team	Member	During	the	Weekdays	
Band	 Description	of	Grade	 Number	of	
Interventions	
Prescriptions	
Reviewed	
Intervention	
Rate	(%)	
4	&	5	 Clinical	pharmacy	
technician	
102	 580	 17.6	
6	 Newly	qualified	
pharmacist	
80	 715	 11.1	
7	 Foundation	level	
pharmacist	
RPS	Advanced	Practice	I	
817	 4974	 16.4	
8a	 Excellence	level	
pharmacist	
RPS	Advanced	Practice	II	
1177	 7825	 15.0	
8b	 Excellence/Mastery	level		
pharmacist**	
896	 5317	 16.9	
8c	 Mastery	level	(consultant)	
pharmacist**	
RPS	Mastery	
222	 983	 22.6	
Total	 	 3294	 20,394*	 16.6%	
*The	total	number	of	prescriptions	reviewed	was	20,517,	however	some	entries	have	missing	bandings	
**The	consultant	pharmacists	were	graded	at	bands	8b	and	8c	
	
	
	
	
	
	
 
